Physician profile
John P Mcgee
NPI 1194104091
$2,708.06
in general payments reported to CMS, 2019-2025
31 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $434 · 2021: $370 · 2022: $681 · 2023: $262 · 2024: $97.81 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $610.05 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $340.94 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $252.11 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $152.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.86 | 2020-2022 | |
| Amarin Pharma, INC. | $121.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.88 | 2019-2021 | |
| Boston Scientific Corporation | $98.74 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.88 | 2019-2022 | |
| Abbott Laboratories | $85.88 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $67.41 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $62.70 | 2022 | |
| Dynavax Technologies Corporation | $61.84 | 2019-2022 | |
| Exact Sciences Corporation | $60.60 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $51.37 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $42.80 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.02 | 2019-2021 | |
| Akcea Therapeutics, INC. | $40.91 | 2019 | |
| Nestle Healthcare Nutrition INC. | $38.16 | 2021-2022 | |
| Abbvie INC. | $36.84 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.86 | 2019-2022 | |
| Corium, LLC | $26.32 | 2023 | Azstarys |
| Esperion Therapeutics, INC. | $24.65 | 2020-2021 | |
| The Binding Site INC. | $19.36 | 2025 | Freelite |
| Tactile Systems Technology INC | $19.10 | 2025 | Flexitouch Plus, Nimbl |
| Phadia US INC. | $16.34 | 2024 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $16.25 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.68 | 2021 | |
| Medtronic, INC. | $15.31 | 2025 | Intellis Adaptivestim |
| Dexcom, INC. | $14.37 | 2022 | |
| Bausch Health US, LLC | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.